Total
0
Shares
Avita Medical (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald
CEO, Dr Michael Perry
Source: CNBC Television
  • Regenerative medicine company AVITA Medical (AVH) has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) to investigate the RECELL System for the treatment of vitiligo
  • Vitiligo is a disease that results in a loss of colour or pigmentation in patches of skin and affects roughly 6.5 million people in the U.S.
  • CEO Dr Mike Perry says the IDE is an important milestone for the company as it looks to advance RECELL
  • RECELL is an alternative and new way to treat burns and reduces the reliance on donors
  • Avita is down 2.55 per cent with shares trading for 47.8 cents each

AVITA Medical (AVH) has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) to investigate the RECELL System for the treatment of vitiligo.

Vitiligo is a disease that results in a loss of colour or pigmentation in patches of skin and affects approximately 6.5 million people in the United States. There is currently no cure or a method of limiting the spread of the disease.

The RECELL System is used to prepare Spray-On-Skin Cells using samples from the patients own skin. This provides a new way to treat burns and reduces the need for donors.

Chief Technology Officer Andrew Quick is looking forward to advancing the RECELL System to clinically treat vitiligo.

"The data from the pivotal trial will form the basis of the FDA submission for consideration to expand the use of the RECELL System for repigmentation of depigmented lesions associated with stable vitiligo," he explained.

CEO Dr Mike Perry says the IDE is an important milestone for the company.

“Globally, the RECELL System is approved for additional skin applications, including vitiligo, which is supported by a substantive body of clinical evidence with patients internationally and in peer-reviewed publications, providing us with valuable experience and confidence in pursuing expanded labelling in the U.S.," he said.

Avita is down 2.55 per cent and currently selling shares for 47.8 cents each at 3:41 pm AEST.


Subscribe


AVH by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New